ENTX Entera Bio Ltd
Price (delayed)
$2.08
Market cap
$75.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.26
Enterprise value
$66.83M
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due
Highlights
Entera Bio's revenue has soared by 159% YoY
The EPS is up by 30% year-on-year and by 7% since the previous quarter
ENTX's quick ratio is up by 43% year-on-year but it is down by 14% since the previous quarter
The equity has declined by 3.7% since the previous quarter but it has increased by 3.6% year-on-year
ENTX's gross margin has dropped by 57% year-on-year
Key stats
What are the main financial stats of ENTX
Market
Valuations
Earnings
Shares outstanding
36.32M
Market cap
$75.56M
Enterprise value
$66.83M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.72
Price to sales (P/S)
1,353.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,172.51
Revenue
$57,000
EBIT
-$8.51M
EBITDA
-$8.46M
Free cash flow
-$7.34M
Per share
Balance sheet
Liquidity
EPS
-$0.26
Free cash flow per share
-$0.2
Book value per share
$0.24
Revenue per share
$0
TBVPS
$0.27
Total assets
$10.04M
Total liabilities
$1.5M
Debt
$334,000
Equity
$8.53M
Working capital
$8.3M
Debt to equity
0.04
Current ratio
7.41
Quick ratio
7.04
Net debt/EBITDA
1.03
Margins
Efficiency
Dividend
EBITDA margin
-14,835.1%
Gross margin
15.8%
Net margin
-14,975.4%
Operating margin
-15,084.2%
Return on assets
-84.1%
Return on equity
-100.4%
Return on invested capital
N/A
Return on capital employed
-97.3%
Return on sales
-14,924.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ENTX stock price
How has the Entera Bio stock price performed over time
Intraday
-1.89%
1 week
16.85%
1 month
27.61%
1 year
215.15%
YTD
246.67%
QTD
13.04%
Financial performance
How have Entera Bio's revenue and profit performed over time
Revenue
$57,000
Gross profit
$9,000
Operating income
-$8.6M
Net income
-$8.54M
Gross margin
15.8%
Net margin
-14,975.4%
Entera Bio's revenue has soared by 159% YoY
The net margin has surged by 69% year-on-year
ENTX's operating margin has surged by 68% year-on-year
ENTX's gross margin has dropped by 57% year-on-year
Growth
What is Entera Bio's growth rate over time
Valuation
What is Entera Bio stock price valuation
P/E
N/A
P/B
8.72
P/S
1,353.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,172.51
The EPS is up by 30% year-on-year and by 7% since the previous quarter
ENTX's P/B is 107% above its 5-year quarterly average of 4.3 and 81% above its last 4 quarters average of 4.9
The equity has declined by 3.7% since the previous quarter but it has increased by 3.6% year-on-year
Entera Bio's revenue has soared by 159% YoY
Efficiency
How efficient is Entera Bio business performance
The return on sales has surged by 69% year-on-year
ENTX's return on equity is down by 4.9% year-on-year but it is up by 2.9% since the previous quarter
Dividends
What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ENTX.
Financial health
How did Entera Bio financials performed over time
ENTX's quick ratio is up by 43% year-on-year but it is down by 14% since the previous quarter
The current ratio is up by 41% year-on-year but it has declined by 15% since the previous quarter
The debt is 96% smaller than the equity
Entera Bio's debt to equity has decreased by 33% YoY
The debt has declined by 27% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.